Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > JD still playing connect the dots
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by InitiumMMXXIIIon May 29, 2024 12:10pm
86 Views
Post# 36062500

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:JD still playing connect the dots

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:JD still playing connect the dotsAlways fun to read your posts, fuzz.

What interest am I to you? Some of you are obsessed with me and it says a lot more about you than it does about me.

Here are my interests, very briefly explained. If an xB3 or p97 fusion protein is developed that depends on xB3 patents then that is something I want to be aware of. Did Rathjen give those rights away? Did Bioasis lose them? The peptide's structure is publicly available. Is somebody using that peptide or 70% or more of its patented structure? Would shareholders have a legal claim to anything of that sort if it's going on?

I can't help it if you, beenthere, zw or TT don't know anything about these things. I know what to watch for and I've set up some watches for some things.

And...

I want Rathjen and the BoD to be aware that somebody who knows something is watching. Nothing (NOTHING!!) based on p97 will get to an FDA IND application without me knowing it. And I don't have to do anything to know that or a host of other possible developments.

The shareholders still own Bioasis. They have rights.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities